The Blood-Brain Barrier Technologies Market in the Asia Pacific is estimated to grow at a prominent CAGR from 2021 to 2026.
A blood-brain barrier acts as a physiological barrier to a molecule that enters or penetrate to the brain. People in this generation are aging too fast than earlier generations. It might be due to habits such as alcohol or drug intake, smoking, unhealthy eating habits, and no physical fitness. The number of people aging will become double the present by the end of 2060. An increased aging population also raises chronic diseases and their prevalence in this region. According to the world health organization, 57% of the global population is currently facing one or the other chronic diseases such as cardiovascular diseases, cancers, neuron disorders, diabetes, etc. The aging brain is more prone to develop degenerative changes, and this requires drug therapy. To deliver the drug, blood-brain barrier technologies are more helpful and make it easier to provide the drug to the active site. This process and technologies are considered most resourceful in brain disorders, Alzheimer’s, epilepsy, Parkinson's diseases, hunter’s syndrome, multiple sclerosis, and its treatment. Hence this trend will increase and boost up the market growth.
The quantitative issue is commonly observed for a few drugs in the process of treatment. For instance, the drugs for a central nervous system such as erythropoietin, Remicade, and Enbrel, which are anti-inflammatory, antibodies do not cross blood-brain barriers in adequate quantities therapeutically. The approval and grants providing committees are expressing stringent regulations for drugs and technologies to get approved. Hence the production unit has to set special standards to meet the rules of these organizations. The regulatory framework and approval time for drugs are negatively affecting this market.
Regional Analysis:
The Asia Pacific is expected to see high growth rates and revenue for blood-brain barrier technologies throughout the forecast period. India and China expect the most massive growth due to its highest population, most extensive patient history and the quick aging process in people, increasing awareness about diseases, early detection and treatment for the same, and high technology. Government initiatives in creating awareness in public about aging and problems associated with aged care for the geriatric population and special healthcare schemes for the old age population also boost the blood-brain barrier technologies market.
Asia is anticipated to show high growth rates in the market forecast period, with China and India being the fastest-growing markets in the Asia Pacific. The primary driving forces for the market in emerging economies are the large pool of patients, growing awareness about the disease, improving healthcare infrastructure, and increasing government funding in the region.
Key players in the market are Bristol-Myers Squibb Company, Pfizer, Inc., biOasia Technologies, Inc., Cypress Biosciences, Inc., Janssen Pharmaceutical N.V., Teva Pharmaceuticals Industries, Ltd., F. Hoffmann La-Roche, Ltd., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., NeuroVive Pharmaceutical AB, and ArmaGen.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Geography
5.1.1 Introduction
5.1.2 Asia Pacific
5.1.2.1 India
5.1.2.2 China
5.1.2.3 Korea
5.1.2.4 Japan
5.1.2.5 Others
5.1.3 Y-o-Y Growth Analysis, By Geography
5.1.4 Market Attractiveness Analysis, By Geography
5.1.5 Market Share Analysis, By Geography
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Allon Therapeutics, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AngioChem Inc.
8.3 Genzyme
8.4 CeNeRx BioPharma, Inc
8.5 Bioasis Technologies Inc.
8.6 Ablynx NV
8.7 Capsulution Pharma AG
8.8 International Brain Barriers Society (IBBS)
8.9 Cephalon Inc
8.10 Cognition Pharmaceuticals LLC
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
